COMP <GO>
CYRX vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
CryoPort Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CYRX 4
— MRK 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $17.29 (-5.47%) • MKT CAP: $926.4M
roic
-11.50%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 47.10% | 74.80% | -27.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -11.50% | 20.70% | -32.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.70% | 3.42% | -6.12 | MRK | /fcf-yield <GO> |
| Operating Margin | -20.90% | 34.30% | -55.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 44.40% | 28.10% | +16.30 | CYRX | /net-margins <GO> |
| Revenue Growth (YoY) | 12.40% | 1.30% | +11.10 | CYRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.33 | 5.19 | -3.86 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 51.7 | +4.90 | CYRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.9x | 18.4x | -8.50 | CYRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $926.4M | $361.02B | -$360.09B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYRX REV | MRK REV | CYRX GROSS % | MRK GROSS % | CYRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $176.2M | $65.01B | 47.1% | 74.8% | -$25.0M | $12.36B |
| FY 2024 | $156.8M | $64.17B | 44.4% | 76.3% | -$33.6M | $18.10B |
| FY 2023 | $168.7M | $60.12B | — | — | -$757.0K | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYRX // BETA —
MRK // BETA 0.92